Search for a command to run...
Older adults face multiple challenges that may negatively affect quality of life, including physical decline, dependency, social isolation, and reduced emotional support. These challenges affect both community-dwelling individuals and those living in nursing homes. This study explores the potential benefits of a multicomponent video call intervention targeting multiple biopsychosocial domains in older adults delivered remotely via the VERA system. A pragmatic, exploratory randomized controlled trial was conducted with 187 participants aged 56 to 101 years, allocated to a control group and an experimental group. Only the experimental group received a multicomponent intervention delivered via video calls over 18 months. Outcomes were assessed at baseline, 9 months, and 18 months across eight domains: cognition, quality of life, depression, perceived loneliness, basic and instrumental activities of daily living, balance, and gait. Standardized instruments were used, including the Mini Mental State Examination (MMSE), FUMAT scale, the abbreviated version of the Yesavage Geriatric Depression Scale (GDS), the revised ESTE scale, the Barthel’s scale, the Lawton and Brody’s test and the Tineti’s scale. Longitudinal changes were analyzed using linear mixed-effects models. Favorable longitudinal changes were observed in the experimental group for cognitive functioning, depressive symptoms, perceived loneliness, quality of life, and basic activities of daily living. Significant group × time interactions indicated differential trajectories compared with the control group. In contrast, no meaningful intervention-related changes were detected for instrumental activities of daily living or balance and gait. The intervention is associated with positive longitudinal changes in several psychosocial and basic functional domains in older adults living at home or in residential care settings. While the findings suggest potential clinical relevance, they should be interpreted within an exploratory framework, and further research is needed to confirm effectiveness, sustainability, and generalizability. The trial was registered on ClinicalTrials.gov (Identifier: NCT07362381).